Shares of Biohaven Ltd. (BHVN) climbed 13% premarket on Monday after the biotech company said its treatment for a rare neurological disorder slowed the progress of the condition in a clinical trial.
Ideaya Biosciences has reported positive interim Phase 2 clinical trial data for darovasertib in neoadjuvant uveal melanoma, or UM, as well as a successful Type C meeting with the Food and Drug ...